16 September 2026 editorial review · Item
Denosumab beta-cell preservation: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: Denosumab's registry requires residual C-peptide and has adult sex-specific age bands. No reported T1D benefit was located. Approval for bone disease does not establish a diabetes indication.
- Registry NCT06524960: RECRUITING; updated 2026-07-28; enrollment 45 (ESTIMATED); primary completion 2027-10-11 (ESTIMATED); results not posted in retrieved record.